ArticleGeburtshilfe und Frauenheilkunde2026
Long-Term Outcomes, Morbidity and Quality of Life in Node-Negative Early-Stage Vulvar Cancer: Sentinel Node Biopsy versus Inguinofemoral Lymphadenectomy.
Article in Geburtshilfe und Frauenheilkunde, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare recurrence, survival, morbidity, and quality of life in early-stage vulvar cancer patients with tumour-free lymph nodes undergoing sentinel lymph node biopsy (SNB) versus inguinofemoral lymphadenectomy (IFL). Study Design: A total of 74 vulvar cancer patients (SNB: n = 58; IFL: n = 16) with a tumour size of < 4 cm and tumour-free lymph nodes were included. Endpoints were overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS). DFS was further divided into local, inguinal, or distant recurrence. Additionally, morbidity and quality of life were analysed. Results: No significant differences in survival outcomes were observed after a median follow-up of 58.0 months for OS, 59.1 months for DSS, and 40.0 months for DFS. Inguinal recurrences occurred in two patients in the SNB group (3.77%) and in none of the patients in the IFL group (0%). However, DFS related to isolated inguinal recurrence did not differ significantly between the groups (96.2% vs. 100%, p = 0.374). Complications were less frequent following SNB, with a significant difference observed only for lymphocele formation (13.8% vs. 50%; p = 0.02). Quality of life scores did not differ significantly between the groups. Conclusion: This study confirms SNB as an oncologically safe procedure. Although inguinal recurrences were slightly more frequent after SNB, there was no significant difference in DSS, DFS, or OS. Lymphocele was significantly more common after IFL, without impacting self-reported quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.